Pharsight

Apadaz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9549923 ZEVRA THERAP Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof
Jul, 2030

(6 years from now)

US9132125 ZEVRA THERAP Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Jul, 2030

(6 years from now)

US8748413 ZEVRA THERAP Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Jul, 2030

(6 years from now)

US8461137 ZEVRA THERAP Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Feb, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828978 ZEVRA THERAP Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Jul, 2030

(6 years from now)

Apadaz is owned by Zevra Therap.

Apadaz contains Acetaminophen; Benzhydrocodone Hydrochloride.

Apadaz has a total of 5 drug patents out of which 0 drug patents have expired.

Apadaz was authorised for market use on 04 January, 2019.

Apadaz is available in tablet;oral dosage forms.

Apadaz can be used as management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

The generics of Apadaz are possible to be released after 22 February, 2031.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 04 January, 2019

Treatment: Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate

Dosage: TABLET;ORAL

More Information on Dosage

APADAZ family patents

Family Patents